menu
    • menu
    [{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Origo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agomab Therapeutics to Acquire Origo Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Agomab","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Agomab"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series B Financing","leadProduct":"ORG-129","moa":"ALK-5","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ORG-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn\u2019s Disease and Starts STENOVA Phase 2a Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AGMB-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series C Financing","leadProduct":"ORG-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AGMB-447","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AGMB-447","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AgomAb Therapeutics N.V

    Menu

    AgomAb Therapeutics N.V

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

                            Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

                            Brand Name : AGMB-447

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2024

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary F...

                            Details : AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under phase 1 clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

                            Brand Name : AGMB-447

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2023

                            Lead Product(s) : AGMB-447

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : EQT Life Sciences

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

                            Details : Proceeds will support Phase 2 candidate AGMB-129/ORG-129 for Fibrostenosing Crohn’s Disease and development of a highly innovative pipeline of anti-fibrotic and regenerative therapies, including AGMB-447 for idiopathic pulmonary fibrosis.

                            Brand Name : AGMB-129

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 11, 2023

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : EQT Life Sciences

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA...

                            Details : AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in...

                            Brand Name : AGMB-129

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 05, 2023

                            Lead Product(s) : AGMB-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn...

                            Details : AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in...

                            Brand Name : AGMB-129

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $114.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million

                            Details : Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers.

                            Brand Name : AGMB-129

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 13, 2022

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Pfizer Inc

                            Deal Size : $114.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Origo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Agomab Therapeutics to Acquire Origo Biopharma

                            Details : The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.

                            Brand Name : ORG-129

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 28, 2021

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Origo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed

                            AgomAb Therapeutics N.V

                            Belgium arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGMB-101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators

                            Details : Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.

                            Brand Name : AGMB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 10, 2021

                            Lead Product(s) : AGMB-101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth